| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Lung cancer is the leading cause of cancer death in Japan. We really need to develop a novel evaluation method for anticancer drug susceptibility. In 80 non-small cell lung cancer patients, we investigated the drug-metabolizing enzyme (Cytochrome P450: CYP), such as CYP1A1, CYP2A6, CYP2E1 and CYP3A) and their relationships to each other and clinical features of the patients. In addition, we investigated the cancer stem cell marker (aldehyde dehydrogenase-1: ALDH1) and their relationships to clinical features in 183 adenocarcinoma patients. Thus, studies of the local expression of drug-metabolizing enzyme and cancer stem cell marker in tumor tissues will provide insights into mechanisms of carcinogenesis and intra-tumor metabolisms of anticancer drugs, which may enable us to develop the present ready-made therapy to the tailor-made therapy.
|
